Fig. 1From: Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) databaseFlowchart demonstrating the adverse event analysis process for deutetrabenazine using the FAERS databaseBack to article page